4//SEC Filing
Szekeres David Leslie 4
Accession 0001209191-23-003564
CIK 0000818033other
Filed
Jan 16, 7:00 PM ET
Accepted
Jan 17, 5:37 PM ET
Size
14.9 KB
Accession
0001209191-23-003564
Insider Transaction Report
Form 4
Szekeres David Leslie
EVP, Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2023-01-13+1,250→ 23,598 total - Tax Payment
Common Stock
2023-01-13$3.17/sh−2,012$6,378→ 26,150 total - Other
Common Stock
2022-10-31$3.27/sh+1,654$5,413→ 22,348 total - Exercise/Conversion
Restricted Stock Units
2023-01-13−4,564→ 32,500 total→ Common Stock (4,564 underlying) - Exercise/Conversion
Restricted Stock Units
2023-01-13−1,250→ 8,750 total→ Common Stock (1,250 underlying) - Exercise/Conversion
Common Stock
2023-01-13+4,564→ 28,162 total
Footnotes (5)
- [F1]Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on October 31, 2022.
- [F2]Restricted stock units convert into common stock on a one-for-one basis.
- [F3]Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.
- [F4]The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).
- [F5]The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).
Documents
Issuer
HERON THERAPEUTICS, INC. /DE/
CIK 0000818033
Entity typeother
Related Parties
1- filerCIK 0001602459
Filing Metadata
- Form type
- 4
- Filed
- Jan 16, 7:00 PM ET
- Accepted
- Jan 17, 5:37 PM ET
- Size
- 14.9 KB